Tranos Paris, Koukoula Stavrenia, de Politis Penelope Burle, Tranou Marianna, Giamouridou Olympia, Stavrakas Panagiotis, Panos Georgios D
Vitreoretinal Department, Ophthalmica Eye Institute, Thessaloniki, Greece.
Department of Ophthalmology, School of Medicine, University of Patras, Patras, Greece.
Drug Des Devel Ther. 2024 Nov 25;18:5367-5375. doi: 10.2147/DDDT.S477677. eCollection 2024.
To evaluate the efficacy of the dexamethasone implant on the electrophysiological profile of Diabetic Macular Oedema (DMO) patients over six months.
In this prospective, single-center study 30 eyes of 22 patients were examined using comprehensive baseline assessments including best-corrected visual acuity (BCVA), central retinal thickness (CRT), contrast sensitivity (CS) and multifocal electroretinogram (mfERG), before and after 0.7mg dexamethasone implant injection, with follow-ups at months 1, 2, 4, and 6. The study employed mixed models to analyse within-subject and between-subject correlations, considering the complexities of multiple measurements per subject.
At baseline, BCVA was 0.66 ± 0.104 logMAR, improving to 0.568 ± 0.104 logMAR by month 6 (P > 0.05). CRT significantly reduced from 521 ± 28.7 μm to 336 ± 28.7 μm (P < 0.05). CS slightly increased from 26.8 ± 1.23 letters to 28.5 ± 1.05 letters (P > 0.05). P wave amplitude saw a notable rise from 33.4 ± 5.66 μV to 47.9 ± 5.43 μV (P < 0.05). P wave implicit time changed minimally from 47.4 ± 0.503 seconds to 48.0 ± 0.503 seconds (P > 0.05). No severe adverse events were recorded.
These results underscore the 0.7mg dexamethasone implant's potential in improving certain electrophysiological markers in DMO, while also highlighting the need for further investigation into its comprehensive impact on retinal function.
评估地塞米松植入物在六个月内对糖尿病性黄斑水肿（DMO）患者电生理特征的疗效。
在这项前瞻性单中心研究中，对22例患者的30只眼睛进行了全面的基线评估，包括最佳矫正视力（BCVA）、中心视网膜厚度（CRT）、对比敏感度（CS）和多焦视网膜电图（mfERG），在注射0.7mg地塞米松植入物之前和之后进行评估，并在第1、2、4和6个月进行随访。该研究采用混合模型分析受试者内和受试者间的相关性，考虑到每个受试者多次测量的复杂性。
基线时，BCVA为0.66±0.104 logMAR，到第6个月时提高到0.568±0.104 logMAR（P>0.05）。CRT从521±28.7μm显著降低至336±28.7μm（P<0.05）。CS从26.8±1.23字母略有增加至28.5±1.05字母（P>0.05）。P波振幅从33.4±5.66μV显著升高至47.9±5.43μV（P<0.05）。P波隐含时间从47.4±0.503秒变化最小至48.0±0.503秒（P>0.05）。未记录到严重不良事件。
这些结果强调了0.7mg地塞米松植入物在改善DMO某些电生理指标方面的潜力，同时也突出了需要进一步研究其对视网膜功能的综合影响。
